Melina Manolas, MD, MPH
@melina_manolas
Followers
11K
Following
9K
Media
404
Statuses
2K
Endocrinologist & Assist Prof @WeillCornell. Hepato-endocrinology #MASLD nerd, digital educator, human being. Views mine.
New York, NY
Joined September 2018
When I was 6 years old, I was already so infatuated with medicine that I begged my pediatrician to take an x-ray of my Telletuby bc I thought he was broken. 20 yrs later, I found it...just as I embark on my own career. If you’ve ever wondered about the inner Poe, here it is!
107
370
8K
Excited to go back to the conference that so warmly welcomed me for my first #TLM 1 year ago. @AASLDtweets Please come to my talk Sunday, Nov 9 with @AASLDPresident ! https://t.co/iAvIFoVA2k
0
2
10
This will kill people
Trump: DON’T TAKE TYLENOL. There is no downside. You will be uncomfortable, it won't be as easy
779
2K
21K
Looking forward to speaking at the upcoming American Association for the Study of Liver Diseases (AASLD) liver meeting in November! I will be speaking about Making Liver Disease Relevant to a Global Audience/Non-Hepatologist Audience! https://t.co/hhbyDEBjc9
0
2
15
Devnet 2.0 is live. Experience the fastest decentralized network for instant payments. ↓
110
73
398
A must-read review in the @NEJM on the most common cause of chronic liver disease: MASLD. All you need to know: trends, pathogenesis, early detection, co-morbidities, lifestyle changes and novel and future drugs….. https://t.co/epAuzLl6E7
4
152
438
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Focus: Why Every Diabetes Provider Needs to Be a Liver Health Champion in 2025 https://t.co/qrgqHUygOY via @doximity
opmed.doximity.com
At the 85th American Diabetes Association (ADA) Scientific Sessions, a clear message emerged: liver health is metabolic health, and diabetes provid...
0
4
15
@melina_manolas Oh wow 🥹 thank you for the kind words @melina_manolas but it was all you, i was just around if you needed anything 😃 good luck on next chapter with @WCMDeptofMed and @WeillCornell ! Its a great team!! We are excited to have a hepato-endocrinologist champion like @scottisaacsmd
0
2
7
Shut down all corrupt pyramid schemes, not the government.
1
4
51
A stepwise, noninvasive strategy with FIB-4 followed by VCTE accurately identifies fibrosis risk in people with suspected #MetALD, helping to catch more cases and reduce missed diagnoses. https://t.co/1APHWYENMJ
0
10
38
In less than a year Dr. @BrettEFortuneMD has helped me advance my research career and helped me create a name for myself in the MASLD space which is my absolute passion. He is a testament to the power of what mentorship and sponsorship can do!!!!
7
5
138
Really important !!! As endocrinology and obesity care providers we have to team up with our GI/Hepatology colleagues to help with metabolic management.
New national survey of hepatology & GI providers: Despite 96% believing weight loss meds help #MASLD, 77% rarely/never prescribe them due to low comfort & limited training. Hunge thanks to @geneyim @MeenaBBansal for leading this effort 👉
0
1
11
🚨 New in @NEJM : Orforglipron, a once-daily oral GLP‑1, led to ~2% A1c drop & ~16 lb weight loss in T2D (ACHIEVE-1 trial). A non-peptide, no-injection option with classic GLP-1 GI profile. Big step for access & adherence! 🔗 https://t.co/aIb2CShopY
nejm.org
Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and ...
1
10
76
We renamed a disease—not for science, but for people. 🩺 Proud to co-author the People-First Liver Charter alongside greats in @NaturePortfolio 🔗 https://t.co/Z6KWYy4k5P Words can heal. Let’s end stigma in MASLD/MASH—across every specialty. 🌍💬
0
4
15
Please disregard the medical opinion of any physician claiming doctors profit off keeping you sick and then in their next breath, try to sell you their own unregulated, non-evidence based supplements.
Doctors shouldn’t be able to get richer, as people get sicker. I’m surprised more people don’t understand why this is a problem
102
697
6K
The Global Think-tank on Steatotic Liver Disease is proud to announce two groundbreaking publications: The People-First Liver Charter, in @NatureMedicine
https://t.co/uUEUCqDp66 2. A call for doubling the MASH diagnostic rate: https://t.co/YZO3UhNlzk
#SLDthinktank #LiverTwitter
thelancet.com
Metabolic dysfunction-associated steatohepatitis (MASH) is an increasingly important contributor to morbidity and mortality. Little emphasis has been placed on its timely diagnosis and interventions...
See you soon Scott and Paul at the Global Think-tank on Steatotic Liver Disease today in Barcelona. The hardworking nurses have been at a training since 9.00am!! Can't wait for your sessions. #SLDthinktank #LiverTwitter
2
10
22
Metabolic dysfunction-associated steatohepatitis (MASH) drives rising morbidity and mortality, yet remains underdiagnosed. A new Health Policy paper by @JVLazarus and colleagues calls for community-based diagnostics: https://t.co/lQ0G6oMOO9
#LiverTwitter #SLDthinktank
thelancet.com
Metabolic dysfunction-associated steatohepatitis (MASH) is an increasingly important contributor to morbidity and mortality. Little emphasis has been placed on its timely diagnosis and interventions...
2
15
32
@LancetRH_Europe Doubling the MASH diagnostic rate was hotly debated at the #SLDthinktank. How do we best do this by 2027? https://t.co/YZO3UhNlzk
@LancetRH_Europe
#LiverTwitter
1
2
10
Equally humbled and excited to be a part of the landmark People-First Liver Charter published today in @Nature !!! A critical step forward in putting those with lived experience at the center of how we discuss & manage chronic liver disease. https://t.co/jzzY3e3xZJ
nature.com
Nature Medicine - Reducing the stigma and discrimination that people living with liver conditions experience requires rethinking how diagnoses, diseases, etiologies and circumstances are perceived...
2
0
13
Maybe it is time to incorporate genetic testing in high risk MASLD? Read everything here 👇👇👇
🧬New 📋 @AjmeraVeeral @JHepatology: In MASLD, inherited genetic risk drives age-associated fibrosis. ⬆️ LSMs after 40y in high-risk genotypes 🧪 PNPLA3 genotyping may improve risk stratification 📈 Supports personalized medicine 🔗 https://t.co/HPja3GnwSy
@DrLoomba @UCSD_GI
0
10
38
🧬New 📋 @AjmeraVeeral @JHepatology: In MASLD, inherited genetic risk drives age-associated fibrosis. ⬆️ LSMs after 40y in high-risk genotypes 🧪 PNPLA3 genotyping may improve risk stratification 📈 Supports personalized medicine 🔗 https://t.co/HPja3GnwSy
@DrLoomba @UCSD_GI
2
23
71
So happy to win 1st place prize for Quality Improvement at the @MontefioreNYC research symposium tonight ! @BrettEFortuneMD and I have worked hard on this endeavor, and much more to come! Next stop... #ADA2025 @AmDiabetesAssn
2
3
79